Interview with Ralf Dahmen, Managing Director, Galderma
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
Address: Level 1, 181 Bay Street, BRIGHTON
VIC 3186, Australia
Tel: +613 9595 3556
Web: http://www.drreddys.com/australia/
Dr. Reddy’s Australia was one of the key sponsors at the annual New South Wales (NSW) Chemists Golf Day. The event saw pharmacists and industry professionals join hands together to help raise funds for building a burn unit at Concord Hospital in NSW.
The event was held at Concord Golf Club, one of the Sydney’s most prestigious golf clubs. A total of 108 people participated in the event. The event raised over $16,000 bringing the total money raised to $96,000 since 2006. The money was donated to the Burns Unit at Concord Hospital which helped fund 12 out of the total 18 rooms in the unit.
Our portfolio of products for the Australian market focuses on various therapeutic areas like Gastro-Intestinal, Anti-Infective, Urology, Cardiovascular diseases, Central Nervous System and Anti-Epileptic.
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
See our Cookie Privacy Policy Here
